Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-01044-8
Abstract: Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We… read more here.
Keywords: inhibitor; orally active; study; selumetinib orally ... See more keywords